Business Context and Reporting Period
This Form 8-K filing by Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) reports a corporate governance event. The report date is February 5, 2025, covering the resignation of a director effective February 6, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the departure of Herbert Conrad from the Board of Directors and his associated committee roles (Audit and Nominating and Corporate Governance Committees). The filing explicitly states this resignation is due to retirement and was not the result of a material disagreement with the Company.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No new risks, contingencies, or unusual items are disclosed in this specific report.
Investor Verification Checklist
- Confirm the effective date of Herbert Conrad's resignation (February 6, 2025).
- Verify the composition of the Board following the resignation to ensure quorum and committee staffing.
- Review subsequent filings for the appointment of a replacement director.
- Check the Company's latest 10-K or 10-Q for current financial status, as this 8-K does not include financial metrics.